ofatumumab

May 22, 2012

FDA Approved Monoclonal Antibodies (mAbs) for Cancer Therapy

March 5, 2011 By MD Becker Partners 3 Comments

Graph of FDA Approved Monoclonal Antibodies (mAbs) for Cancer Therapy

The following image may be reproduced without modification using the attribution “Graph source – MD Becker Partners (www.mdbpartners.com).” Click on the image to enlarge.

Filed Under: Facts & Figures Tagged With: alemtuzumab, bevacizumab, biotechnology, cancer therapy, cetuximab, FDA, gemtuzumab ozogamicin, ibrituxomab tiuxetan, ipilimumab, monoclonal antibodies, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL